Regulation of Retinal Proteome by Topical Antiglaucomatous Eye Drops in an Inherited Glaucoma Rat Model
Overview
Affiliations
Examination of the response of the retinal proteome to elevated intraocular pressure (IOP) and to the pharmacological normalization of IOP is crucial, in order to develop drugs with neuroptorective potential. We used a hereditary rat model of ocular hypertension to lower IOP with travaprost and dorzolamide applied topically on the eye surface, and examine changes of the retinal proteome. Our data demonstrate that elevated IOP causes alterations in the retinal protein profile, in particular in high-mobility-group-protein B1 (HMGB1), calmodulin, heat-shock-protein (HSP) 70 and carbonic anhydrase II expression. The changes of the retinal proteome by dorzolamide or travoprost are different and independent of the IOP lowering effect. This fact suggests that the eye drops exert a direct IOP-independent effect on retinal metabolism. Further investigations are required to elucidate the potential neuroprotective mechanisms signaled through changes of HMGB1, calmodulin, HSP70 and carbonic anhydrase II expression in glaucoma. The data may facilitate development of eye drops that exert neuroprotection through direct pharmacological effect.
Zaman K, Nguyen V, Prokai-Tatrai K, Prokai L Int J Mol Sci. 2023; 24(16).
PMID: 37628770 PMC: 10454042. DOI: 10.3390/ijms241612592.
Retinal ganglion cell-specific genetic regulation in primary open-angle glaucoma.
Daniszewski M, Senabouth A, Liang H, Han X, Lidgerwood G, Hernandez D Cell Genom. 2023; 2(6):100142.
PMID: 36778138 PMC: 9903700. DOI: 10.1016/j.xgen.2022.100142.
Mass spectrometry-based retina proteomics.
Prokai L, Zaman K, Prokai-Tatrai K Mass Spectrom Rev. 2022; 42(3):1032-1062.
PMID: 35670041 PMC: 9730434. DOI: 10.1002/mas.21786.
Tonner H, Hunn S, Auler N, Schmelter C, Beutgen V, von Pein H Int J Mol Sci. 2022; 23(8).
PMID: 35456925 PMC: 9028318. DOI: 10.3390/ijms23084107.
Valdes-Sanchez L, Calado S, de la Cerda B, Aramburu A, Garcia-Delgado A, Massalini S Mol Med. 2020; 26(1):1.
PMID: 31892304 PMC: 6938640. DOI: 10.1186/s10020-019-0124-z.